期刊
HEALTH ECONOMICS
卷 24, 期 10, 页码 1256-1271出版社
WILEY
DOI: 10.1002/hec.3086
关键词
health technology assessment; implicit weights; cost-effectiveness; National Institute for Health and Care Excellence (NICE); logistic regression
资金
- Amgen
- AstraZeneca
- BMS
- Celgene UK Ireland
- GSK
- Lilly UK
- Merck
- Merck Serono
- Pfizer
- Sanofi Aventis
- Schering Plough
- Takeda UK
- Wyeth
The National Institute for Health and Care Excellence (NICE) emphasises that cost-effectiveness is not the only consideration in health technology appraisal and is increasingly explicit about other factors considered relevant but not the weight attached to each. The objective of this study is to investigate the influence of cost-effectiveness and other factors on NICE decisions and whether NICE's decision-making has changed over time. We model NICE's decisions as binary choices for or against a health care technology in a specific patient group. Independent variables comprised of the following: clinical and economic evidence; characteristics of patients, disease or treatment; and contextual factors potentially affecting decision-making. Data on all NICE decisions published by December 2011 were obtained from HTAinSite [www.htainsite.com]. Cost-effectiveness alone correctly predicted 82% of decisions; few other variables were significant and alternative model specifications had similar performance. There was no evidence that the threshold has changed significantly over time. The model with highest prediction accuracy suggested that technologies costing 40000 per quality-adjusted life-year (QALY) have a 50% chance of NICE rejection (75% at 52000 pound/QALY; 25% at 27000 pound/QALY). Past NICE decisions appear to have been based on a higher threshold than 20000- pound 30000 pound/QALY. However, this may reflect consideration of other factors that cannot be easily quantified. (c) 2014 The Authors. Health Economics published by John Wiley & Sons Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据